Tegatrabetan

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406595

CAS#: 1227637-23-1

Description: Tegatrabetan, also known as Tegavivint and BC2059, is an orally bioavailable and potent β-catenin inhibitor. BC2059 potently induces apoptosis as a single agent and in combination with bortezomib in multiple myeloma. BC2059 induced apoptosis in 10/10 genetically heterogeneous human myeloma cell lines (HMCL) treated with dosages ranging from 50-500nM.


Chemical Structure

img
Tegatrabetan
CAS# 1227637-23-1

Theoretical Analysis

MedKoo Cat#: 406595
Name: Tegatrabetan
CAS#: 1227637-23-1
Chemical Formula: C28H36N4O6S2
Exact Mass: 588.20763
Molecular Weight: 588.74
Elemental Analysis: C, 57.12; H, 6.16; N, 9.52; O, 16.31; S, 10.89

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-02-24. Prices are subject to change without notice.

Tegatrabetan is not available.

Synonym: BC2059; BC-2059; BC 2059; tegavivint; Tegatrabetan,

IUPAC/Chemical Name: (9E,10E)-2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime

InChi Key: GAPRVZKWPDRAJA-TVRZPQSBSA-N

InChi Code: InChI=1S/C28H36N4O6S2/c1-17-9-18(2)14-31(13-17)39(35,36)21-5-7-23-25(11-21)28(30-34)26-12-22(6-8-24(26)27(23)29-33)40(37,38)32-15-19(3)10-20(4)16-32/h5-8,11-12,17-20,33-34H,9-10,13-16H2,1-4H3/b29-27-,30-28+/t17-,18+,19-,20+

SMILES Code: O=S(C1=CC2=C(C=C1)/C(C3=CC=C(S(=O)(N4C[C@H](C)C[C@H](C)C4)=O)C=C3/C2=N\O)=N\O)(N5C[C@H](C)C[C@H](C)C5)=O

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 588.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C,  Zu Y, Iyer S, Bhalla KN. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia. 2014 Dec 8. doi: 10.1038/leu.2014.340. [Epub ahead of print] PubMed PMID: 25482131.  



Additional Information

BC2059 disrupts the WNT/beta-catenin pathway in human tumor cells. In cancer cells, BC2059 potently inhibits the WNT/beta catenin pathway as measured by modulation of clinically relevant target gene expression and a specific decrease in beta catenin protein levels. The mechanism of action for BC2059 is targeted degradation of beta catenin protein in cancer cells followed by reduced expression of beta-catenin-regulated genes that are known to promote and maintain the malignant phenotype. This results in cell cycle arrest and subsequent apoptosis.